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Abstract 
Inflammatory biomarkers are considered by modern researchers as one of the best markers of 
effectiveness of inhaled corticosteroids (ICS) at patients with COPD, but there are a few studies about 
their prediction opportunity for COPD progression. 
The study is devoted to study of the diagnostic value of some markers of systemic inflammation (CRP, 
fibrinogen, MMP-2 and -9, hyaluronic acid (HA) at patients with COPD, there role as predictors of 
COPD progression. 
It was determined that determination of dynamic levels of such marker of systemic inflammation as 
MMP-2, CRP, HA can be used as parameters for further evaluation of the clinical stability of patients 
during their long-term follow-up. 
Significant decreasing of inflammatory markers shows the adequacy of anti-inflammatory therapy of 
patients with COPD regardless of changes in lung function dynamic disorders. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) progression is variable. Some patients have a 
relatively stable course, while others suffer relentless progression leading to severe 
breathlessness, frequent acute exacerbations of COPD (AECOPD), respiratory failure and 
death [7]. 
There are many studies in which inflammatory biomarkers have been used in an attempt to 
predict future exacerbations and progression; it is likely that these biomarkers represent a 
consequence rather than the cause [6]. 
The purpose of major modern researches is to examine if COPD phenotypes and systemic 
inflammatory markers predict the risk for COPD exacerbations, defined as requiring treatment 
with either systemic steroids or antibiotics [10]. For examples recent studies show that COPD 
patients exhibit low-grade systemic inflammation, and that plasma fibrinogen and high 
neutrophil counts are related to faster declines in lung function [8, 10]. It was established that 
high serum C-reactive protein (CRP) and matrix metalloproteinase (MMP)-9 levels were 
related to FEV1 decline. 
But most of studies try to predict not progression in general but time to the next exacerbation [6, 
7]. Inflammatory biomarkers are considered by modern researchers as one of the best markers 
of effectiveness of inhaled corticosteroids (ICS) in COPD patients, but there are a few studies 
about their prediction opportunity for COPD progression. 
The aim of our study was to establish the diagnostic value of some markers of systemic 
inflammation (CRP, fibrinogen, MMP-2 and -9, hyaluronic acid (HA)) in COPD patients as 
predictors of COPD progression. 
Materials and methods. 50 COPD patients (age – 62,1±0,91 years) formed a main group, 
which was divided into subgroups according to the FEV1 level: subgroup 1 – 25 patients (age – 
61,8±1,60 years, men – 24 (96,0%)) with GOLD II, subgroup 2 – 25 patients (age – 66,2±1,28 
years, men – 24 (96,0%)) with GOLD III. All patients accepted therapy (bronchodilators (BD) 
or ICS according to the stage of disease) variably. 
Analyses of complaints, disease histories, clinical and functional examination, markers’ levels, 
adjusted patients’ drug therapy were done at visit 1. On this visit basic treatment was 
prescribed to patients: patients of subgroup 1 used basic treatment with long acting muscarinic 
agonists (LAMA) once daily, patients of subgroup 2 – with ICS and long acting beta-agonists 
(LABA) twice a day. 
Than all patients visited us every three months in the following way: visit 2 – in 3 months, 
visit 3 – in 6 months, visit 4 – in 9 months after correction of the treatment.
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The control group consisted of 26 healthy persons (age- 
58,9±11,5 years, men – 18 (69,2%). 
Methods included clinical data, spirometry, plasma levels of 
CRP, fibrinogen MMP-2 and -9, HA. 
COPD diagnoses were formulated and basic treatment was 
prescribed in compliance with the recommendations of the 
Order of the Ministry of Healthcare of Ukraine №555 from 27 
June 2013 [2]. 
The research of the external respiration function (ERF) with a 
characteristic of the main bronchial obstruction indicators 
(forced vital capacity of lungs (FVCL), pulmonary forced 
expiratory volume in 1 minute (FEV1) was conducted using 
computer spirograph “Master Screen Body/Diff” (“Jager”, 
Germany). The reversibility test was made using 400 mcg of 
salbutamol. 
CRP level in blood plasma was determined by quantitative 
immunological method [3]. The levels of MMP-2 and -9 in 
plasma were determined by ELISA [9]. The level of fibrinogen 
in the blood plasma was determined by Clauss method [4]. The 
level of HA in plasma was determined by a modified ELISA 
Gold 5]. 
Statistical methods were conducted by biometric analysis 
implemented in the EXCEL-2003 (№ 74017-641-9475201-
57075), STATISTICA 6.0 (№ 31415926535897) program 
packages 1. 
 
Results. All the 50 patients were involved in the research in 
stable phase of COPD. On the stages of long-term dynamic 
follow-up (when making further visits with biomarkers levels 
identification) none of the patients revealed any clinical signs 
of infective exacerbation of the disease. Not a single patient 
was excluded from the study. 
On visit 1 in subgroup 1 mean FEV1(post) was 67,7±1,65% 
pred., in subgroup 2 – 37,5±1,61% pred. 
In general levels of inflammatory markers in COPD patients 
on visit 1 were significantly higher than in control group (table 
1), but in subgroups they were almost identical. 
 
Тable 1: Dynamic of biomarkers of patients with COPD 
 
Parameter Main group Control group visit 1 visit 2 visit 3 visit 4 
C-RP, mg/l 9,2±0,91* 7,8±0,55 7,1±0,43 6,4±0,34 6,25±0,14 
fibrinogen, g/l 3,1±0,10* 3,0±0,09* 2,9±0,09* 2,6±0,09* 2,85±0,17 
MMP-2, cu 131,5±6,58* 126,3±5,28* 125,1±3,99* 100,0±2,96 92,5±4,10 
MMP-9, cu 171,1±13,10* 143,0±7,74* 138,4±8,36* 109,5±3,20 103,1±5,55 
HA, mg/ml 0,28±0,01* 0,23±0,01* 0,20±0,01 0,13±0,01 0,15±0,02 
Note. * – p<0,05 with control group 
 
In a year it was progressively aggravation of disease in 9 
(18,0%) COPD patients (8 patients from subgroup 1 and 1 
patient from subgroup 2), which was accompanied with 
decreasing of FEV1. Corresponding to dynamic of FEV1 
patients of subgroup 1 were divided into 2 cohorts: subgroup 
1A – with improvement of FEV1, subgroup 1B – with 
decreasing of FEV1 (table 2). 
 
Table 2: Dynamic level of FEV1 in COPD patients 
 
Subgroups n FEV1 (post), % pred. p by Wilcoxon visit 1 visit 4 
1 25 67,7±1,65 71,1±2,15 0,110 
1A 17 66,7±1,54 76,0±1,25 0,000 
1B 8 69,8±3,60 60,8±4,28 0,013 
2 25 37,5±1,61 50,1±2,23 0,000 
 
The results showed that the level of CRP was significantly 
decreased in the subgroup 1A after 1 year of systemic 
administration of appropriate therapy, in the subgroup 1B it 
was almost unchanged; levels of other markers of systemic 
inflammation decreased in the both subgroups 1A and 1B, i.e. 
regardless of the FEV1 dynamics (table 3).  
In the subgroup 2 after 1 year of adequate therapy parameters 
of systemic inflammation markers was significantly decreased 
(table 3). Thus, the results indicate that during adequate 
therapy the severity of systemic inflammation is greatly 
reduced at COPD patients of both GOLD II and GOLD III 
regardless of changes in lung function dynamic disorders. 
 
Conclusions 
1. Determination of dynamic levels of such marker of 
systemic inflammation as MMP-2, CRP, HA can be used 
as parameters for further evaluation of the clinical stability 
of patients during their long-term follow-up. 
2. Significant decreasing of inflammatory markers shows the 
adequacy of anti-inflammatory therapy of patients with 
COPD regardless of changes in lung function dynamic 
disorders. 
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